Biology and management of inflammatory breast cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 209-220

  Dawood, Shaheenah ^a  

^a DUBAI HEALTH AUTHORITY   (United Arab Emirates)

Author keywords

Clinical definition; Clinical trial; Epidemiology; Inflammatory breast cancer; Molecular markers; Multidisciplinary management; Prognostic factor

Indexed keywords

ANGIOGENIC FACTOR; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GUANOSINE TRIPHOSPHATASE; LAPATINIB; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SEMAXANIB; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; UVOMORULIN; VANDETANIB;

ADD ON THERAPY; ALGORITHM; AXILLARY LYMPH NODE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FATALITY; GENETIC ANALYSIS; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMAGING; INFLAMMATORY BREAST CANCER; MASTECTOMY; MASTITIS; PALLIATIVE THERAPY; RADIATION DOSE; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; UNITED STATES; VASCULAR TUMOR;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 76749157243     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.90     Document Type: Review

References (107)

1. Lee BJ, Tannenbaum EN. Inflammatory carcinoma of the breast. Surg. Gynecol. Obstet. 39, 580-595 (1924).
2. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J. Natl Cancer Inst. 74(2), 291-297 (1985).
3. Green FL, Page DL, Fleming ID et al. Breast. In: AAJCC Cancer Staging Manual (6th edition). Springer-Verlag, NY, USA 225-281 (2002).
4. Bozzetti F, Saccozzi R, De Lena M et al. Inflammatory cancer of the breast: analysis of 114 cases. J. Surg. Oncol. 18(4), 355-361 (1981).
5. Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology 121(1), 173-176 (1976).
6. Zucali R, Uslenghi C, Kenda R et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37(3), 1422-1431 (1976).
7. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J. Natl Cancer Inst. 97(13), 966-975 (2005). • Large population-based epidemiological study of inflammatory breast cancer (IBC).
8. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer 82(12), 2366-2372 (1998).
9. Wingo PA, Jaminson PM, Young JL, Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15(3), 321-328 (2004).
10. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J. Clin. Oncol. 16(12), 3731-3735 (1998).
11. Mourali N, Muenz LR, Tabbane F et al. Epidemiological features of rapidly progressing breast cancer in Tunisia. Cancer 46(12), 2741-2746 (1980).
12. Maalej M, Frikha H, Ben Salem S et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull. Cancer 86(3), 302-306 (1999).
13. Levine PH, Pogo BG, Coronel S et al. Increasing evidence for a human breast cancer virus with geographic differences. Cancer 101(4), 721-726 (2004).
14. Shiramizu B, Barriga F, Neequaye J et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 77(7), 1516-1526 (1991).
15. Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am. J. Cancer 33, 33-49 (1938).
16. Haagensen CD. Inflammatory carcinoma. In: Diseases of the Breast. WB Saunders, PA, USA, 488-498 (1956).
17. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J. Clin. Oncol. 10(6), 1014-1024 (1992).
18. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin. Breast Cancer 5(5), 386-395 (2006).
19. Attia-Sobol J, Ferrière JP, Curé H, Kwiatkowski F et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur. J. Cancer 29(8), 1081-1088 (1993).
20. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2(6), 423-429 (2000).
21. Delarue JC, May-Levin F, Mouriesse H et al. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumors of the human breast. Br. J. Cancer 44(6), 911-916 (1981).
22. Bonnier P, Charpin C, Lejeune C et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int. J. Cancer 62(4), 382-385 (1995).
23. Jardines L, Haffty BG, Theriault RL. Locally advanced, locally recurrent and metastatic breast cancer. In: Cancer Management. A Multidisciplinary Approach (3rd edition). Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). Melville, NY, USA, 73-88 (1999)
24. Harvey HA, Lipton A, Lawrence BV et al. Estrogen receptor status in inflammatory breast carcinoma. J. Surg. Oncol. 21(1), 42-44 (1982).
25. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin. Cancer Res. 12(17), 5047-5054 (2006).
26. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer 43(2), 201-208 (1989).
27. Guerin M, Sheng ZM, Andrieu N et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5(1), 131-135 (1990).
28. Parton M, Dowsett M, Ashley S et al. Highincidence of HER-2 positivity in inflammatory breast cancer. Breast 13(2), 97-103 (2004).
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
30. Dawood S, Broglio K, Gong Y et al. Inflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112(9), 1905-1911 (2008). •• Retrospective study looking at the prognostic significance of HER2 in IBC and survival advantage conferred by trastuzumab in HER2-positive IBC.
31. Yonish-Rouach E, Resnitzky D, Lotem J et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352(6333), 345-347 (1991).
32. Aas T, Borresen AL, Geisler S et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2(7), 811-814 (1996).
33. Feki A, Irminger-Finger I. Muational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52(2), 103-116 (2004).
34. Angulo-Gonzalez AM, Sneige N, Kau SW et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin. Cancer Res. 10(18), 6215-6221 (2004).
35. Riou G, Lê MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J. Natl Cancer Inst. 85(21), 1765-1767 (1993).
36. Gamallo C, Palacios J, Suarez A et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol. 142(4), 987-993 (1993).
37. Oka H, Shiozaki H, Kobayashi K et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 53, 1696-1701 (1993).
38. Alpaugh ML, Tomlinson JS, Shao ZM et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 59(20), 5079-5084 (1999).
39. Tomlinson JS, Alpaugh MK, Barsky SH. An intact overexpressed E-cadherin/a, b-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 61(13), 5231-5241 (2001).
40. Hoffmeyer MR, Wall KM, Dharmawardhane SF. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int. 5(1), 11 (2005).
41. Kleer CG, van Golen KL, Braun T et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 14(5), 458-464 (2001).
42. Van der Auwera I, Van Laere SJ, Van Den Eynden GG et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res. 10(23), 7965-7971 (2004).
43. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst. 84(24), 1875-1887 (1992).
44. Colpaert CG , Vermeulen PB, Benoy I et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br. J. Cancer 88(5), 718-725 (2003).
45. Gonzalez-Angulo AM, Guarneri V, Gong Y et al. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin. Breast Cancer 7, 326-330 (2006).
46. Cabioglu N, Gong Y, Islam R et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann. Oncol. 18(4), 1021-1029 (2007).
47. Gong Y, Gonzalez-Angulo Am, Broglio K et al. Expression of Notch-1 and B-catenin: defining the molecular portrait of inflammatory breast cancer. Breast Cancer Res. Treat. 100, S299 (2006).
48. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60(20), 5832-5838 (2000).
49. van Golen KL, Davies S, Wu ZF et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res. 5(9), 2511-2519 (1999).
50. Kleer CG, Griffith KA, Sabel MS et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res. Treat. 93(2), 101-110 (2005).
51. Kleer CG, Zhang Y, Pan Q et al. WISP3 isa novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21(20), 3172-3180 (2002).
52. Kleer CG, Zhang Y, Pan Q et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. Treat. 6(2), 110-115 (2004).
53. Van Laere S, Van der Auwera I, Van den Eynden GG et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res. Treat. 93(3), 237-246 (2005).
54. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 64(23), 8558-8565 (2004).
55. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 65(6), 2170-2178 (2005).
56. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
57. Van Laere SJ, Van den Eynden GG, Van der Auwera I et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res. Treat. 95(3), 243-255 (2006).
58. Van Laere S, Van der Auwera I, Van den Eynden G et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br. J. Cancer 97(8), 1165-1174 (2007).
59. Zhang X, Lin M, van Golen KI, Yoshioka K et al. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-1) stimulated breast cancer cell migration. Breast Cancer Res. Treat. 93(2), 159-168 (2005).
60. Günhan-Bilgen I, Ustün EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 223(3), 829-838 (2002).
61. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis. 22, 45-54 (2005).
62. Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res. Treat. 109(3), 417-426 (2008).
63. Rieber A, Brambs HJ, Gabelmann A et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 12(7), 1711-1719 (2002).
64. Rosen EL, Blackwell KL, Baker JA et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am. J. Roentgenol. 181(5), 1275-1282 (2003).
65. Thukral A, Thomasson DM, Chow CK et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab - initial experience. Radiology 244(3), 727-735 (2007).
66. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 22, 67-73 (2005-2006).
67. Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology 121(1), 173-176 (1976).
68. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37(3), 1422-1431 (1976).
69. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathological primary tumor axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17(2), 460-469 (1999).
70. Dawood S, Gonzalez-Angulo AM, Peintinger F et al . Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D Anderson experience. Cancer 110(6), 1195-1200 (2007).
71. Ueno NT, Buzdar AU, Singeltary SE et al. Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D Anderson Center. Cancer Chemother. Pharmacol. 40(4), 321-329 (1997). •• Combined analysis of four prospective trials demonstrating the survival advantage conferred by the use of an anthracycline polychemotherapy regimen among women with IBC.
72. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN et al. Disease-free and overall survival after pathological complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106(5), 1000-1006 (2006).
73. Early Breast Cancer Trialists' Collaborative group: effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365(9472), 1687-1717 (2005).
74. Baldini E, Gardin G, Evangelista G et al. Long-term results of combined-modality therapy for inflammatory breast cancer. Clin. Breast Cancer 5(5), 358-363 (2004).
75. Harris EE, Schultz D, Bertsch H et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1200-1208 (2003).
76. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D Anderson Cancer Center experience. Clin. Breast Cancer 4(6), 415-419 (2004).
77. Low JA, Berman AW, Steinberg SM et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J. Clin. Oncol. 22(20), 4067-4074 (2004).
78. Veyret C, Levy C, Chollet P et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant study group GETIS 02 trial. Cancer 107(11), 2535-2544 (2006).
79. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1684 (2005).
80. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
81. Slamon DJ, Leyland-Jones B, Shak S et al. Human breast cancer: use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
82. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth receptor 2-positive operable breast cancer. J. Clin. Oncol. 23(16), 3676-3685 (2005).
83. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-postive locally advanced breast cancer. J. Clin. Oncol. 24(12), 1831-1838 (2006).
84. Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer 4(5), 348-353 (2003).
85. Limentani SA, Brufsky AM, Erban JK et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J. Clin. Oncol. 25(10), 1232-1238 (2007).
86. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. 21(15), 46-53 (2003).
87. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at: San Antonio Breast Cancer Conference. San Antonio, TX, USA 10-14 December (2008) (Abstract31).
88. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41), 6255-6263 (2002).
89. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
90. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23(23), 5305-5313 (2005).
91. Spector NL, Blackwell K, Hurley J et al. EGF103009, a Phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. 24(18S), 502 (2006) (Abstract 502).
92. Cristofanilli M, Boussen H, Baselga J et al. A Phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res. Treat. (2006) (Abstract 1).
93. Somlo G, Frankel P, Chow W et al. Prognostic indictors and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J. Clin. Oncol. 22(10), 1839-1848 (2004).
94. Cheng YC, Rondon G, Yang Y et al. The use of high dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol. Blood Marrow Transplant. 10(11), 794-804 (2004).
95. Veins P, Palangie T, Janvier M et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br. J. Cancer 81(13), 449-456 (1999).
96. Perez CA, Fields JN, Fracasso PM et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 74, 466-476 (1994).
97. Flemming RY, Asmar L, Buzdar AU et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann. Surg. Oncol. 4(6), 452-461 (1997).
98. Stearns V, Ewing CA, Slack R, Penannen MF et al. Sentinel lymphadenopathy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann. Surg. Oncol. 9(3), 235-242 (2002).
99. Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin. Oncol. 35(1), 78-86 (2008).
100. Liao Z, Strom EA, Buzdar AU et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int. J. Radiat. Oncol. Biol. Phys. 47(5), 1191-2000 (2000).
101. Stopeck A, Sheldon M, Vahedian M et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 8(9), 2798-2805 (2002).
102. Miller KD, Trigo JM, Wheeler C et al. A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 11(9), 3369-3376 (2005).
103. Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 25(4), 792-799 (2005).
104. Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117-124 (2003).
105. Wedam SB, Low JA, Yang XC et al. Anti-angiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24(5), 769-777 (2006).
106. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9(2), 115-119 (2007).
107. Jonston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 21(13), 2492-2499 (2003).